Rosetta Genomics Q4 Revenues Slide 62 Percent

CEO Kenneth Berlin said that the company's focus will be directed at the commercialization of its miRview mets tests.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories